+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutic Drug Monitoring Market - Global Forecast to 2030- Product Image
Therapeutic Drug Monitoring Market - Global Forecast to 2030- Product Image
Sale

Therapeutic Drug Monitoring Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5367869
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Therapeutic Drug Monitoring Market grew from USD 4.38 billion in 2024 to USD 5.11 billion in 2025. It is expected to continue growing at a CAGR of 16.21%, reaching USD 10.80 billion by 2030.

Therapeutic Drug Monitoring (TDM) has evolved into an essential component of precision medicine, ensuring that patients receive optimal drug dosages tailored to their individual metabolic profiles. As polypharmacy becomes more common and novel therapies enter the market, the complexity of maintaining therapeutic windows intensifies. This dynamic landscape demands reliable analytical platforms, robust clinical workflows, and data-driven decision support systems. In this context, the importance of continuous measurement and adjustment of drug concentrations cannot be overstated: it directly influences patient safety, treatment efficacy, and the reduction of adverse events. Recent advances in instrumentation, bioinformatics, and point-of-care solutions are reshaping the execution of TDM across both hospital and research settings. As regulatory bodies tighten quality standards and reimbursement models pivot toward value-based care, stakeholders must navigate shifting priorities to align technological innovation with clinical outcomes. This executive summary offers a comprehensive overview of the forces driving change, explores key market segments and regional dynamics, and provides actionable guidance for industry leaders looking to strengthen their competitive position in the rapidly maturing TDM domain.

Transformative Shifts in the Therapeutic Drug Monitoring Landscape

Shifts in regulatory requirements and clinical guidelines have prompted a wave of technological renewal. Chromatographic methodologies, driven by deeper integration of high-performance liquid chromatography with tandem mass spectrometry, are redefining sensitivity thresholds, while immunoassays leverage enhanced antibody specificity and multiplexing capabilities. Spectrometric techniques are further bolstered by real-time data analytics and machine learning algorithms that expedite peak identification and automate quality control. Concurrently, personalized medicine initiatives are fueling demand for point-of-care TDM platforms, enabling rapid bedside measurement of drug levels for critical care and outpatient settings alike. The convergence of digital health records with laboratory information systems has streamlined test ordering, result reporting, and protocol adherence, supporting interdisciplinary collaboration and closed-loop dosing adjustments. Beyond technology, strategic alliances among diagnostic laboratories, pharmaceutical developers, and academic institutions have accelerated translational research efforts, advancing biomarker discovery and validating novel therapeutic indices. This transformative period positions TDM not merely as a monitoring tool, but as a proactive mechanism for optimizing drug regimens, minimizing toxicity, and improving long-term patient outcomes.

Cumulative Impact of United States Tariffs 2025

The introduction of new tariffs by the United States in 2025 has exerted significant pressure on the importation of reagents, consumables, and precision instrumentation essential to TDM workflows. As border duties escalate, cost structures for gas chromatography-mass spectrometry columns, high-performance liquid chromatography solvents, antibody reagents, and specialized assay kits have undergone upward adjustment. Diagnostic laboratories and hospital networks are reassessing procurement strategies, exploring domestic suppliers and regional distribution hubs to mitigate supply chain risk. Manufacturers, in turn, are revisiting price models and advancing local manufacturing initiatives to maintain competitive pricing and ensure regulatory compliance. These adjustments have ripple effects across pricing negotiations with payers, prompting stakeholders to advocate for updated reimbursement policies that reflect increased operational expenditures. From a strategic standpoint, organizations that proactively engage with customs authorities, diversify sourcing regions, and invest in tariff-resilient manufacturing will be best positioned to sustain supply continuity and cost efficiency in the post-tariff environment.

Key Segmentation Insights

In the technology segment, chromatographic methodologies continue to dominate, with gas chromatography-mass spectrometry leading applications that demand ultra-trace detection, while normal phase and reversed-phase high-performance liquid chromatography carve out niches in polar and nonpolar analyte separation. Immunoassays maintain strong momentum, particularly enzyme-linked immunosorbent assays and fluorescence polarization immunoassays, which benefit from streamlined workflows and scalability. Spectrometric techniques, anchored by advanced mass spectrometry and nuclear magnetic resonance spectroscopy, are gaining traction for comprehensive metabolite profiling. Within drug class segmentation, antibiotics-especially beta-lactam antibiotics and macrolides-remain a cornerstone, though new generation antiepileptics are rapidly expanding coverage due to their narrow therapeutic indices. Cardiovascular drugs, notably antiarrhythmics and anticoagulants, underscore the critical need for frequent monitoring, while immunosuppressants such as calcineurin inhibitors command attention post-transplant. End user insights reveal that hospital-associated diagnostic laboratories drive volume, yet independent laboratories and academic research institutes are emerging as innovation hubs. Serum and plasma samples persist as the primary matrices for TDM, with urine monitoring-24-hour and random collections-and whole blood analysis via capillary or venous draws offering complementary perspectives. Finally, quantitative assays, including calibration assays and quality control services, underpin laboratory accuracy and regulatory compliance, outperforming qualitative and semi-quantitative formats in high-throughput settings.

Key Regional Insights

The Americas exhibit a robust adoption curve, spurred by well-established healthcare infrastructures, favorable reimbursement frameworks, and a strong presence of multinational diagnostic companies. In contrast, the Europe, Middle East & Africa region demonstrates diverse market dynamics: Western Europe prioritizes advanced instrumentation integration, while emerging markets in Eastern Europe and the Middle East focus on building diagnostics capacity and local manufacturing partnerships. Africa’s growth is tempered by infrastructure challenges, yet targeted public-private collaborations offer promising trajectories. The Asia-Pacific region delivers the highest growth potential, driven by expanding hospital networks, government initiatives to improve laboratory accreditation, and the rise of domestic equipment manufacturers. Countries such as China and India are investing heavily in local R&D, while Southeast Asian markets show increasing demand for point-of-care solutions in rural and under-served areas. Overall, regional strategies must balance investment in cutting-edge technologies with initiatives to strengthen training, logistics, and regulatory harmonization.

Key Companies Insights

The competitive landscape is marked by a blend of established conglomerates and specialized innovators. Abbott Laboratories leverages its global footprint to integrate immunoassay platforms with digital connectivity, while Agilent Technologies, Inc. advances mass spectrometry solutions optimized for clinical workflows. apDia Group and ARK Diagnostics, Inc. focus on niche assay development, and ARUP Laboratories offers comprehensive reference testing services. Assay Genie and Bio-Rad Laboratories, Inc. are renowned for antibody and reagent quality, whereas bioMérieux SA expands its clinical chemistry portfolio. Bühlmann Laboratories AG and Cambridge Life Sciences Limited excel in point-of-care calibration services, and Cardinal Health, Inc. delivers supply chain solutions tailored to laboratory needs. Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, and DiaSorin SpA drive instrumental innovation, with Danaher also encompassing Beckman Coulter technologies. DiaSystem Scandinavia AB and Eagle Biosciences, Inc. support specialized assay kits, while Exagen Inc. pioneers autoantibody monitoring. F. Hoffmann-La Roche AG and Grifols, S.A. emphasize global clinical trial collaborations, and H.U. Group Holdings, Inc. addresses niche markets in Asia. Krishgen Biosystems and Myriad Genetics, Inc. explore genomic integration, while Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. underpin the market with end-to-end platforms. Neoteryx, LLC by Trajan Group, OneCare Media, LLC, Pfizer Inc., R-Biopharm AG, Randox Laboratories, Ltd., Sekisui Chemical Co Ltd., Svar Life Science AB, Tecan Trading AG, Theradiag SA, and Veolia Group round out the competitive ecosystem, each contributing specialized solutions in sample collection, assay design, laboratory automation, and environmental compliance.

Actionable Recommendations for Industry Leaders

  1. Prioritize investment in integrated digital platforms that connect laboratory instruments, electronic health records, and decision support tools, ensuring seamless data flow and accelerating clinical decision making.
  2. Diversify supply chains by establishing regional partnerships and dual-sourcing critical reagents and consumables, mitigating the impact of tariffs and logistics disruptions.
  3. Expand point-of-care offerings for critical care and outpatient settings, leveraging compact immunoassay and spectrometric devices to deliver rapid, bedside drug concentration results.
  4. Collaborate with academic research centers to co-develop novel biomarkers and validate emerging therapeutic indices, strengthening the evidentiary base for regulatory approvals.
  5. Implement advanced analytics and machine learning pipelines to automate peak integration, trend analysis, and quality assurance, reducing manual review times and improving throughput.
  6. Engage with policymakers and payers to advocate for updated reimbursement models that reflect the value of TDM in reducing hospitalizations, preventing toxicity, and optimizing therapeutic outcomes.

Conclusion: Aligning Innovation with Clinical Excellence

As therapeutic drug monitoring continues to mature, stakeholders must embrace a holistic approach that aligns technological innovation, regulatory foresight, and clinical collaboration. By integrating advanced analytical platforms with robust data ecosystems and forging resilient supply chains, organizations can sustain competitive differentiation and deliver measurable patient benefits. The convergence of personalized medicine principles, digital health strategies, and value-based care will shape the next phase of growth, positioning TDM as an indispensable tool for optimizing pharmacotherapy. Leaders who proactively invest in training, infrastructure, and cross-sector partnerships will secure accelerated adoption, improved operational efficiency, and stronger market resilience in an increasingly complex global environment.

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Chromatographic Methodologies
    • Gas Chromatography-Mass Spectrometry (GC-MS)
    • High-Performance Liquid Chromatography (HPLC)
      • Normal Phase HPLC
      • Reversed-Phase HPLC
  • Immunoassays
    • Enzyme-Linked Immunosorbent Assays (ELISA)
    • Fluorescence Polarization Immunoassays
    • Radioimmunoassays
  • Spectrometric Techniques
    • Mass Spectrometry
    • Nuclear Magnetic Resonance Spectroscopy
  • Antibiotics
    • Beta-Lactam Antibiotics
    • Macrolides
  • Antiepileptics
    • New Generation Antiepileptics
    • Traditional Antiepileptics
  • Cardiovascular Drugs
    • Antiarrhythmics
    • Anticoagulants
  • Immunosuppressants
    • Calcineurin Inhibitors
    • mTOR Inhibitors
  • Diagnostic Laboratories
    • Hospital-Associated Laboratories
    • Independent Laboratories
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Institutes
    • Academic Research Institutes
    • Government Research Institutes
  • Serum/Plasma
  • Urine
    • 24-Hour Urine
    • Random Urine
  • Whole Blood
    • Capillary Blood
    • Venous Blood
  • Qualitative Assays
  • Quantitative Assays
    • Calibration Assays
    • Quality Control Services
  • Semi-Quantitative Assays

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Therapeutic Drug Monitoring Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • apDia Group
  • ARK Diagnostics, Inc.
  • ARUP Laboratories
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Bühlmann Laboratories AG
  • Cambridge Life Sciences Limited
  • Cardinal Health, Inc.
  • Chromsystems Instruments & Chemicals GmbH
  • Danaher Corporation
  • DiaSorin SpA
  • DiaSystem Scandinavia AB
  • Eagle Biosciences, Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • H.U. Group Holdings, Inc.
  • Krishgen Biosystems
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Neoteryx, LLC by Trajan Group
  • OneCare Media, LLC
  • Pfizer Inc.
  • R-Biopharm AG
  • Randox Laboratories, Ltd.
  • Sekisui Chemical Co Ltd.
  • Siemens Healthineers AG
  • Svar Life Science AB
  • Tecan Trading AG
  • Theradiag SA
  • Thermo Fisher Scientific, Inc.
  • Veolia Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Therapeutic Drug Monitoring Market, by Technology Type
8.1. Introduction
8.2. Chromatographic Methodologies
8.2.1. Gas Chromatography-Mass Spectrometry (GC-MS)
8.2.2. High-Performance Liquid Chromatography (HPLC)
8.2.2.1. Normal Phase HPLC
8.2.2.2. Reversed-Phase HPLC
8.3. Immunoassays
8.3.1. Enzyme-Linked Immunosorbent Assays (ELISA)
8.3.2. Fluorescence Polarization Immunoassays
8.3.3. Radioimmunoassays
8.4. Spectrometric Techniques
8.4.1. Mass Spectrometry
8.4.2. Nuclear Magnetic Resonance Spectroscopy
9. Therapeutic Drug Monitoring Market, by Drug Class
9.1. Introduction
9.2. Antibiotics
9.2.1. Beta-Lactam Antibiotics
9.2.2. Macrolides
9.3. Antiepileptics
9.3.1. New Generation Antiepileptics
9.3.2. Traditional Antiepileptics
9.4. Cardiovascular Drugs
9.4.1. Antiarrhythmics
9.4.2. Anticoagulants
9.5. Immunosuppressants
9.5.1. Calcineurin Inhibitors
9.5.2. mTOR Inhibitors
10. Therapeutic Drug Monitoring Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Hospital-Associated Laboratories
10.2.2. Independent Laboratories
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Research Institutes
10.4.1. Academic Research Institutes
10.4.2. Government Research Institutes
11. Therapeutic Drug Monitoring Market, by Sample Type
11.1. Introduction
11.2. Serum/Plasma
11.3. Urine
11.3.1. 24-Hour Urine
11.3.2. Random Urine
11.4. Whole Blood
11.4.1. Capillary Blood
11.4.2. Venous Blood
12. Therapeutic Drug Monitoring Market, by Assay Type
12.1. Introduction
12.2. Qualitative Assays
12.3. Quantitative Assays
12.3.1. Calibration Assays
12.3.2. Quality Control Services
12.4. Semi-Quantitative Assays
13. Americas Therapeutic Drug Monitoring Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Therapeutic Drug Monitoring Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Therapeutic Drug Monitoring Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Agilent Technologies, Inc.
16.3.3. apDia Group
16.3.4. ARK Diagnostics, Inc.
16.3.5. ARUP Laboratories
16.3.6. Assay Genie
16.3.7. Bio-Rad Laboratories, Inc.
16.3.8. bioMérieux SA
16.3.9. Bühlmann Laboratories AG
16.3.10. Cambridge Life Sciences Limited
16.3.11. Cardinal Health, Inc.
16.3.12. Chromsystems Instruments & Chemicals GmbH
16.3.13. Danaher Corporation
16.3.14. DiaSorin SpA
16.3.15. DiaSystem Scandinavia AB
16.3.16. Eagle Biosciences, Inc.
16.3.17. Exagen Inc.
16.3.18. F. Hoffmann-La Roche AG
16.3.19. Grifols, S.A.
16.3.20. H.U. Group Holdings, Inc.
16.3.21. Krishgen Biosystems
16.3.22. Merck KGaA
16.3.23. Myriad Genetics, Inc.
16.3.24. Neoteryx, LLC by Trajan Group
16.3.25. OneCare Media, LLC
16.3.26. Pfizer Inc.
16.3.27. R-Biopharm AG
16.3.28. Randox Laboratories, Ltd.
16.3.29. Sekisui Chemical Co Ltd.
16.3.30. Siemens Healthineers AG
16.3.31. Svar Life Science AB
16.3.32. Tecan Trading AG
16.3.33. Theradiag SA
16.3.34. Thermo Fisher Scientific, Inc.
16.3.35. Veolia Group
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET MULTI-CURRENCY
FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET MULTI-LANGUAGE
FIGURE 3. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS), BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY NORMAL PHASE HPLC, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REVERSED-PHASE HPLC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE POLARIZATION IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BETA-LACTAM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY NEW GENERATION ANTIEPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TRADITIONAL ANTIEPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL-ASSOCIATED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY 24-HOUR URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RANDOM URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUALITATIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CALIBRATION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SEMI-QUANTITATIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 73. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 112. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 128. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 129. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 130. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 131. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 132. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 133. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 135. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 136. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 137. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 138. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 140. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 142. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 143. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 144. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 145. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 146. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 148. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 149. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 150. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 152. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 159. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 161. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 162. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 163. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 164. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 165. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 225. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 226. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 227. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 228. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 229. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 230. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 232. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 233. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 234. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 235. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 237. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 239. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 241. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 242. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 243. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 244. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 246. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 247. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 248. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 249. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 251. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 252. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 253. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 254. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 256. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 258. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 259. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 260. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 261. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 262. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 266. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 282. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 283. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 284. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 285. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 286. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 287. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 294. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 296. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 297. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 298. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY WHOLE BLOOD, 2018-2030 (USD MILLION)
TABLE 299. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ASSAY TYPE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY QUANTITATIVE ASSAYS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHIC METHODOLOGIES, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SPECTROMETRIC TECHNIQUES, 2018-2030 (USD MILLION)
T

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • apDia Group
  • ARK Diagnostics, Inc.
  • ARUP Laboratories
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Bühlmann Laboratories AG
  • Cambridge Life Sciences Limited
  • Cardinal Health, Inc.
  • Chromsystems Instruments & Chemicals GmbH
  • Danaher Corporation
  • DiaSorin SpA
  • DiaSystem Scandinavia AB
  • Eagle Biosciences, Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • H.U. Group Holdings, Inc.
  • Krishgen Biosystems
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Neoteryx, LLC by Trajan Group
  • OneCare Media, LLC
  • Pfizer Inc.
  • R-Biopharm AG
  • Randox Laboratories, Ltd.
  • Sekisui Chemical Co Ltd.
  • Siemens Healthineers AG
  • Svar Life Science AB
  • Tecan Trading AG
  • Theradiag SA
  • Thermo Fisher Scientific, Inc.
  • Veolia Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Therapeutic Drug Monitoring Market by Product, Technology, Drug Class, Therapeutic Area, Specimen, End User - Global Forecast to 2029 - Product Image

Therapeutic Drug Monitoring Market by Product, Technology, Drug Class, Therapeutic Area, Specimen, End User - Global Forecast to 2029

  • Report
  • 381 Pages
  • Global
From
Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Therapeutic Drug Monitoring Market Report 2025 - Product Image

Therapeutic Drug Monitoring Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Therapeutic Drug Monitoring - Global Strategic Business Report - Product Image

Therapeutic Drug Monitoring - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Therapeutic Drug Monitoring Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Therapeutic Drug Monitoring Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 153 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.